Literature DB >> 19423728

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Mojgan Ahmadzadeh1, Laura A Johnson, Bianca Heemskerk, John R Wunderlich, Mark E Dudley, Donald E White, Steven A Rosenberg.   

Abstract

Tumor antigen-specific T cells are found within melanomas, yet tumors continue to grow. Although the tumor microenvironment is thought to influence the suppression of tumor-reactive T cells, the underlying mechanisms for this T-cell dysfunction are not clear. Here, we report that the majority of tumor infiltrating T lymphocytes (TIL), including MART-1/Melan-A melanoma antigen-specific CD8 T cells, predominantly expressed PD-1, in contrast to T cells in normal tissues and peripheral blood T lymphocytes (PBL). PD-1(+) TIL expressed CTLA-4 and Ki-67, markers that were not expressed by PD-1(-) TIL and T cells in the normal tissues and PBL. Moreover, PD-1(+) TIL were primarily HLA-DR(+) and CD127(-), in contrast to PD-1(-) TIL. Effector cytokine production by PD-1(+) TIL was impaired compared with PD-1(-) TIL and PBL. Collectively, the phenotypic and functional characterizations of TIL revealed a significantly higher frequency and level of PD-1 expression on TIL compared with normal tissue T-cell infiltrates and PBL, and PD-1 expression correlated with an exhausted phenotype and impaired effector function. These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423728      PMCID: PMC2927090          DOI: 10.1182/blood-2008-12-195792

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Immune resistance orchestrated by the tumor microenvironment.

Authors:  Thomas F Gajewski; Yuru Meng; Christian Blank; Ian Brown; Aalok Kacha; Justin Kline; Helena Harlin
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

2.  Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.

Authors:  Jianping Huang; Keith W Kerstann; Mojgan Ahmadzadeh; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

3.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

4.  IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.

Authors:  Steven A Rosenberg; Claude Sportès; Mojgan Ahmadzadeh; Terry J Fry; Lien T Ngo; Susan L Schwarz; Maryalice Stetler-Stevenson; Kathleen E Morton; Sharon A Mavroukakis; Michel Morre; Renaud Buffet; Crystal L Mackall; Ronald E Gress
Journal:  J Immunother       Date:  2006 May-Jun       Impact factor: 4.456

Review 5.  Immune suppression in the tumor microenvironment.

Authors:  Thomas F Gajewski; Yuru Meng; Helena Harlin
Journal:  J Immunother       Date:  2006 May-Jun       Impact factor: 4.456

6.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

7.  CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.

Authors:  Richard V Parry; Jens M Chemnitz; Kenneth A Frauwirth; Anthony R Lanfranco; Inbal Braunstein; Sumire V Kobayashi; Peter S Linsley; Craig B Thompson; James L Riley
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

8.  FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.

Authors:  Mojgan Ahmadzadeh; Aloisio Felipe-Silva; Bianca Heemskerk; Daniel J Powell; John R Wunderlich; Maria J Merino; Steven A Rosenberg
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

9.  Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.

Authors:  Christian Blank; Juergen Kuball; Simon Voelkl; Heinz Wiendl; Bernd Becker; Bernhard Walter; Otto Majdic; Thomas F Gajewski; Mathias Theobald; Reinhard Andreesen; Andreas Mackensen
Journal:  Int J Cancer       Date:  2006-07-15       Impact factor: 7.396

10.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Authors:  Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

View more
  697 in total

1.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 3.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

4.  Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.

Authors:  Kimberly Loo; Katy K Tsai; Kelly Mahuron; Jacqueline Liu; Mariela L Pauli; Priscila M Sandoval; Adi Nosrati; James Lee; Lawrence Chen; Jimmy Hwang; Lauren S Levine; Matthew F Krummel; Alain P Algazi; Miguel Pampaloni; Michael D Alvarado; Michael D Rosenblum; Adil I Daud
Journal:  JCI Insight       Date:  2017-07-20

Review 5.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  Melanoma in immunosuppressed patients.

Authors:  Agnieszka W Kubica; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

7.  N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.

Authors:  Matthew J Scheffel; Gina Scurti; Megan M Wyatt; Elizabeth Garrett-Mayer; Chrystal M Paulos; Michael I Nishimura; Christina Voelkel-Johnson
Journal:  Cancer Immunol Immunother       Date:  2018-02-02       Impact factor: 6.968

Review 8.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

9.  Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.

Authors:  Christian A Bauer; Edward Y Kim; Francesco Marangoni; Esteban Carrizosa; Natalie M Claudio; Thorsten R Mempel
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

Review 10.  Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Authors:  Kim A Reiss; Patrick M Forde; Julie R Brahmer
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.